EXICURE, INC. OCI, before Reclassifications, Net of Tax, Attributable to Parent
EXICURE, INC. (XCUR) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of $2.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2023-03-27
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2022-12-31 was $1.00K.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2022-09-30 was $4.00K.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2022-06-30 was $0.00.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2022-03-31 was -$3.00K.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was $2.00K.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2021 was -$84.00K, a 178.50% decline from fiscal 2020.
- EXICURE, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2020 was $107.00K.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-27 | $5.00K derived: sum of 2 quarters · filed 2023-03-27 | $5.00K derived: sum of 3 quarters · filed 2023-03-27 | $2.00K 10-K · filed 2023-03-27 |
| 2022-09-30 | $4.00K 10-Q · filed 2022-11-14 | $4.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | -$3.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2022-03-31 | -$3.00K 10-Q · filed 2022-11-14 | |||
| 2021-12-31 | -$84.00K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | -$5.00K 10-Q · filed 2022-11-14 | -$32.00K derived: sum of 2 quarters · filed 2022-11-14 | -$83.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$27.00K 10-Q · filed 2022-11-14 | -$78.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | -$51.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $107.00K 10-K · filed 2022-03-25 | |||
| 2020-09-30 | -$138.00K 10-Q · filed 2021-11-19 | $214.00K derived: sum of 2 quarters · filed 2021-11-19 | $224.00K derived: sum of 3 quarters · filed 2021-11-19 | |
| 2020-06-30 | $352.00K 10-Q · filed 2021-11-19 | $362.00K derived: sum of 2 quarters · filed 2021-11-19 | ||
| 2020-03-31 | $10.00K 10-Q · filed 2021-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |